117
Participants
Start Date
October 1, 2018
Primary Completion Date
November 6, 2024
Study Completion Date
November 6, 2024
Crizanlizumab
Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
Novartis Investigative Site, Muscat
Novartis Investigative Site, Brussels
Novartis Investigative Site, Laken
Novartis Investigative Site, Tripoli
Novartis Investigative Site, Liège
Novartis Investigative Site, Orbassano
Childrens Hospital at Montefiore, The Bronx
Childrens National Hospital, Washington D.C.
Duke University Medical Center, Durham
East Carolina University, Greenville
Novartis Investigative Site, Madrid
Medical Uni of South Carolina, Charleston
Childrens Healthcare of Atlanta, Atlanta
University of Florida, Gainesville
Joe DiMaggio Childrens Hospital, Hollywood
Novartis Investigative Site, Mersin
Novartis Investigative Site, Padua
University Of Alabama, Birmingham
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Paris
Cook Childrens Medical Center, Fort Worth
Novartis Investigative Site, Montería
Novartis Investigative Site, Nagpur
Novartis Investigative Site, Santiago de Cali
Childrens Hosp Boston Dept of Hematology, Boston
Childrens Hospital Of Philadelphia, Philadelphia
Novartis Investigative Site, Salvador
Novartis Investigative Site, Ribeirão Preto
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Montreal
Novartis Investigative Site, Beirut
Novartis Investigative Site, Palma de Mallorca
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Adana
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY